GlassScriptPhysician profile
Shaifali Dugar
NPI 1528385739
$12,547.92
in general payments reported to CMS, 2019-2025
32 companies · $1,805 in 2025
The $1,805 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,380 · 2020: $519 · 2021: $1,351 · 2022: $2,097 · 2023: $2,377 · 2024: $2,018 · 2025: $1,805.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,814 · Education: $387.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,813.88 |
| Education | $387.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,856.23 | 2019-2025 | Rinvoq, Skyrizi |
| Amgen INC. | $1,677.72 | 2019-2025 | Enbrel, Otezla, Evenity |
| Pfizer INC. | $1,461.69 | 2019-2025 | |
| Janssen Biotech, INC. | $1,008.14 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $956.22 | 2019-2025 | Taltz, Zepbound |
| Ucb, INC. | $875.35 | 2019-2025 | Cimzia, Bimzelx |
| Horizon Therapeutics Plc | $673.30 | 2019-2023 | Krystexxa |
| Glaxosmithkline, LLC. | $665.58 | 2019-2025 | Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $597.38 | 2019-2025 | Ofev, Cyltezo |
| Mallinckrodt Hospital Products INC. | $524.97 | 2020-2025 | Acthar |
| Novartis Pharmaceuticals Corporation | $482.69 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $258.27 | 2022-2024 | Saphnelo |
| E.R. Squibb & Sons, L.L.C. | $224.87 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $162.32 | 2025 | Tremfya |
| Celgene Corporation | $159.92 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $156.25 | 2024-2025 | Purified Cortrophin Gel |
| Scilex Pharmaceuticals INC. | $138.41 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $126.70 | 2023-2025 | Strensiq |
| Sandoz INC. | $91.32 | 2023-2025 | Hyrimoz, Jubbonti |
| Mallinckrodt Enterprises LLC | $81.67 | 2019 | |
| Aurinia Pharma U.S., INC. | $59.68 | 2021-2024 | Lupkynis |
| Depuy Synthes Sales INC. | $56.36 | 2019-2022 | |
| Bioventus LLC | $38.73 | 2019 | |
| Genentech USA, INC. | $34.18 | 2019 | |
| Exact Sciences Corporation | $31.94 | 2025 | Cologuard Collection Kit |
| Mylan Institutional INC. | $28.47 | 2023 | |
| Genzyme Corporation | $23.63 | 2023 | |
| Oxford Immunotec USA INC | $22.28 | 2022 | |
| Octapharma USA, INC. | $21.12 | 2025 | Octagam Immune Globulin (Human) |
| Regeneron Healthcare Solutions, INC. | $20.01 | 2019 | |
| Invivyd INC | $19.75 | 2025 | Pemgarda |
| Hikma Pharmaceuticals USA | $12.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaifali Dugar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.